RCM
AGRX

RA Capital Management’s Agile Therapeutics AGRX Stock Holding History

RA Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-427
Closed -$6.49M – 35
2016
Q2 		$6.49M Sell
427
-105
-20% -$1.44M 0.9% 22
2016
Q1 		$6.61M Buy
+532
New +$6.87M 0.84% 29
2015
Q4 		– Sell
-315
Closed -$4.25M – 51
2015
Q3 		$4.25M Sell
315
-414
-57% -$7.35M 0.61% 36
2015
Q2 		$12.5M Hold
729
– – 1.26% 27
2015
Q1 		$13.5M Buy
+729
New +$12.8M 1.34% 21

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RA Capital Management's AGRX Position: Q3 2016 in Review

RA Capital Management sold out of Agile Therapeutics (AGRX) in Q3 2016, closing a stake of 427 shares — an estimated $6.49M sold.

RA Capital Management first reported a position in AGRX in Q1 2015 and held it in 5 quarters. The position peaked at $13.5M in Q1 2015. 51 funds tracked by Wall St. Rank hold AGRX as of Q3 2016.

  • RA Capital Management reported no remaining Agile Therapeutics position as of Q3 2016 after selling out during the quarter.
  • RA Capital Management sold 427 Agile Therapeutics shares in Q3 2016, an estimated $6.49M.
  • RA Capital Management first reported a position in Agile Therapeutics in Q1 2015 and held it in 5 quarters.
  • RA Capital Management's Agile Therapeutics position peaked at $13.5M in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2016.

Based on RA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.